TABLE 2.
Cause summary of death due to hematologic adverse events.
| Drugs | Cause of TRAE death | Number | Study |
|---|---|---|---|
| Pembrolizumab | Decreased WBC count | 1 | KEYNOTE-181 |
| Pembrolizumab plus chemotherapy | Febrile neutropenia | 2 | KEYNOTE-062 |
| KEYNOTE-590 | |||
| Nivolumab plus chemotherapy | Febrile neutropenia | 3 | ATTRACTION-4 |
| CHECKMATE 649 | |||
| Camrelizumab plus chemotherapy | Anemia | 1 | ESCORT-1st |
| Sintilimab plus chemotherapy | Myelosuppression | 1 | ORIENT-15 |
| Decrease in platelet count | 1 | ||
| Chemotherapy with or without placebo | Decreased neutrophil count | 1 | KEYNOTE-181 |
| Febrile neutropenia | 1 | KEYNOTE-590 | |
| Hemolytic anemia | 1 | ATTRACTION-4 | |
| Decreased platelet count | 1 | ORIENT-15 | |
| Total | 13 |
Abbreviations: TRAE, treatment related adverse event; WBC, white blood cell.